Chronic Total Occlusion Market Scope And Analysis

Report Code : TIPMD00002711
Category : Life Sciences

No. of Pages : 150

Buy Now

Chronic Total Occlusion Market Analysis, Scope, and Growth by 2031

Buy Now

Chronic Total Occlusion Market Report Scope

Report Attribute	Details
Market size in 2022	US$ 395.66 Million
Market Size by 2031	US$ 801.16 Million
Global CAGR (2023 - 2031)	8.23%
Historical Data	2021-2022
Forecast period	2023-2031
Segments Covered	By Equipment Guide Wires Micro Catheters Crossing Devices Re-Entry Devices By End User Hospitals Ambulatory Care Centers By End User Pharmaceutical Companies Biopharmaceutical Companies Contract Research Organizations
Regions and Countries Covered	North America US Canada Mexico Europe UK Germany France Russia Italy Rest of Europe Asia-Pacific China India Japan Australia Rest of Asia-Pacific South and Central America Brazil Argentina Rest of South and Central America Middle East and Africa South Africa Saudi Arabia UAE Rest of Middle East and Africa
Market leaders and key company profiles	Boston Scientific Medtronic CR Bard Terumo Corporation Abbott Integer Holdings Corporation Baylis Medical Company

Chronic Total Occlusion Market News and Recent Developments

The Chronic Total Occlusion Market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. The following is a list of developments in the market for Chronic Total Occlusion:

Reflow Medical, Inc. made an official declaration regarding the FDA commercial authorization it has obtained for its coraCatheters, an extensive collection of cutting-edge microcatheters specifically designed for percutaneous coronary interventions to access and traverse intricate and demanding lesions. The most recent addition to Reflow's portfolio of innovative devices is the coraCatheters family, which also comprises the Wingman and Spex Catheters. As the company establishes itself as an industry leader in coronary care, it is augmenting its sales force to assist present and forthcoming advancements. (Source: Reflow Medical., Press Release/Company Website/Newsletter, May 2023)
Nitiloop Ltd. to received a 510(k) clearance from the U.S. Food & Drug Administration for its NovaCross CTO Microcatheter. The NovaCross CTO Microcatheter device is intended to facilitate the intraluminal placement of conventional and steerable guidewires beyond stenotic lesions, including chronic total occlusions (CTO), before PTCA or stent intervention. It is also intended to be used in conjunction with a steerable guidewire to access discrete regions of the coronary and peripheral vasculature and for guidewire exchange. (Source: Nitiloop Incorporated., Press Release/Company Website/Newsletter, April 2020)

Chronic Total Occlusion Market Report Coverage and Deliverables

The “Chronic Total Occlusion Market Size and Forecast (2021–2031)” report provides a detailed analysis of the market covering below areas:

Market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
Market dynamics such as drivers, restraints, and key opportunities
Key future trends
Detailed PEST and SWOT analysis
Global and regional market analysis covering key market trends, major players, regulations, and recent market developments
Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments
Detailed company profiles